One important clinical PET/MRI application using PSMA ligands is its use after previous negative biopsies in patients with high suspicion of PCa, implied by a sudden or drastic increase in prostate-specific antigen (PSA) in their blood. The gene discussed is FOLH1; the disease is posterior cortical atrophy.